Proposal for pathogenesis-based treatment options to reduce calcium oxalate stone recurrence.
| Autor: | Khan SR; Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA., Canales BK; Department of Urology, University of Florida, Gainesville, FL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Asian journal of urology [Asian J Urol] 2023 Jul; Vol. 10 (3), pp. 246-257. Date of Electronic Publication: 2023 Apr 13. |
| DOI: | 10.1016/j.ajur.2023.01.008 |
| Abstrakt: | Objective: Prevalence of kidney stone disease continues to increase globally with recurrence rates between 30% and 50% despite technological and scientific advances. Reduction in recurrence would improve patient outcomes and reduce cost and stone morbidities. Our objective was to review results of experimental studies performed to determine the efficacy of readily available compounds that can be used to prevent recurrence. Methods: All relevant literature up to October 2020, listed in PubMed is reviewed. Results: Clinical guidelines endorse the use of evidence-based medications, such as alkaline agents and thiazides, to reduce urinary mineral supersaturation and recurrence. However, there may be additional steps during stone pathogenesis where medications could moderate stone risk. Idiopathic calcium oxalate stones grow attached to Randall's plaques or plugs. Results of clinical and experimental studies suggest involvement of reactive oxygen species and oxidative stress in the formation of both the plaques and plugs. The renin-angiotensin-aldosterone system (RAAS), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mitochondria, and NOD-like receptor pyrin domain containing-3 (NLRP3) inflammasome have all been implicated at specific steps during stone pathogenesis in animal models. Conclusion: In addition to supersaturation-reducing therapies, the use of anti-oxidants, free radical scavengers, and inhibitors of NADPH oxidase, NLRP3 inflammasome, and RAAS may prove beneficial for stone prevention. Compounds such as statins and angiotensin converting enzyme inhibitors are already in use as therapeutics for hypertension and cardio-vascular disease and have previously shown to reduce calcium oxalate nephrolithiasis in rats. Although clinical evidence for their use in stone prevention in humans is limited, experimental data support they be considered along with standard evidence-based medications and clinical expertise when patients are being counselled for stone prevention. Competing Interests: The authors declare no conflict of interest. (© 2023 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|